Therapeutic cancer vaccines: Are we there yet?

Klebanoff, Christopher A.; Acquavella, Nicolas; Yu, Zhiya; Restifo, Nicholas P.

doi:10.1111/j.1600-065x.2010.00979.x

Cited by 272Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Therapeutic cancer vaccines: Are we there yet?

Open access

Klebanoff, Christopher A., Acquavella, Nicolas, Yu, Zhiya, Restifo, Nicholas P.·2011·Immunological Reviews

DOI 10.1111/j.1600-065x.2010.00979.xPMC PMC3075547

Open this paper in CoChat — free account

Abstract

Summary: Enthusiasm for therapeutic cancer vaccines has been rejuvenated with the recent completion of several large, randomized phase III clinical trials that in some cases have reported an improvement in progression free or overall survival. However, an honest appraisal of their efficacy reveals modest clinical benefit and a frequent requirement for patients with relatively indolent cancers and minimal or no measurable disease. Experience with adoptive cell transfer‐based immunotherapies unequivocally establishes that T cells can mediate durable complete responses, even in the setting of advanced metastatic disease. Further, these findings reveal that the successful vaccines of the future must confront: (i) a corrupted tumor microenvironment containing regulatory T cells and aberrantly matured myeloid cells, (ii) a tumor‐specific T‐cell repertoire that is prone to immunologic exhaustion and senescence, and (iii) highly mutable tumor targets capable of antigen loss and immune evasion. Future progress may come from innovations in the development of selective preparative regimens that eliminate or neutralize suppressive cellular populations, more effective immunologic adjuvants, and further refinement of agents capable of antagonizing immune check‐point blockade pathways.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1600-065x.2010.00979.x

Cites

210 of 210 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Whole tumor vaccines tend to exhibit poor immunogenicity, and the immune response elicited by these vaccines is often inadequate to confer significant benefits to patients.
“Additionally, whole tumor vaccines tend to exhibit poor immunogenicity. Consequently, the immune response elicited by these vaccines is often inadequate to confer significant benefits to patients, as demonstrated by the average outcomes observed in previous studies [150].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [150]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · see citing works
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · see citing works
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665 · see citing works
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645 · see citing works
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I. J., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,542 · see citing works
Approaching the asymptote? Evolution and revolution in immunology.Preprint
Janeway, C. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.003 · Cited by 3,396 · see citing works
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214 · see citing works
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,956 · see citing works
Self-citation
CTLA-4 Control over Foxp3 <sup>+</sup> Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · see citing works
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,803 · see citing works
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · see citing works
Self-citation
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · see citing works
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
The FUTURE II Study Group (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,056 · see citing works
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043 · see citing works
Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883 · see citing works
Effector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865 · cited 1× · see citing works
“The paradigm for a prototypical naive T-cell response to an antigenic challenge, such as an acute viral infection, is that responding T cells undergo a multi-log clonal expansion, acquire effector functions and permeate peripheral tissues, clear the instigating pathogen, and subsequently contract to form a durable pop…”
Background
Lineage relationship and protective immunity of memory CD8 T cell subsets
Wherry, E. J., Teichgräber, V., Becker, T. C., Masopust, D., Kaech, S. M., Antia, R., von Andrian, U. H., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni889 · Cited by 1,864 · see citing works
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786 · see citing works
Self-citation
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625 · see citing works
Self-citation
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · see citing works
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559 · see citing works
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works
Self-citation
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355 · see citing works
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Dudley, M. E., Yang, J. C., Sherry, R. M., Hughes, M. S., Royal, R. E., Kammula, U. S., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,334 · see citing works
Self-citation
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Paavonen, J. A., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S., Apter, D. L., Kitchener, H. C., Castellsagué, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,313 · see citing works
Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells
Kaech, S. M., & Ahmed, R. (2001) · Nature Immunology · doi:10.1038/87720 · Cited by 1,277 · see citing works
Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P. C., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206 · see citing works
Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M., & Greenberg, P. D. (1992) · Science · doi:10.1126/science.1352912 · Cited by 1,202 · see citing works
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Pulè, M. A., Savoldo, B., Myers, G. D., Rössig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195 · see citing works
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · see citing works
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108 · see citing works
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,063 · see citing works
Self-citation
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031 · see citing works
Self-citation
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · see citing works
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology and Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,006 · see citing works
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glodé, L. M., Bilhartz, D. L., Wyand, M. S., Manson, K. H., Panicali, D., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 981 · see citing works
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works
Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells
Klebanoff, C. A., Gattinoni, L., Torabi‐Parizi, P., Kerstann, K. W., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503726102 · Cited by 961 · see citing works
Self-citation
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 947 · see citing works
Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth‐Dreese, F. A., Dellemijn, T. A. M., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 927 · see citing works
Self-citation
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N. H., Wallen, H. D., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R. M., Jungbluth, A. A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 904 · see citing works
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887 · see citing works
Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation
van Stipdonk, M. J. B., Lemmens, E. E., & Schoenberger, S. P. (2001) · Nature Immunology · doi:10.1038/87730 · Cited by 846 · see citing works
Tumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P. J., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 838 · see citing works
Self-citation
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer
Higano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J. J., Yuh, L., Provost, N. M., & Frohlich, M. W. (2009) · Cancer · doi:10.1002/cncr.24429 · Cited by 809 · see citing works
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells
Antony, P. A., Piccirillo, C. A., Akpınarlı, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C., Klebanoff, C. A., Overwijk, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2591 · Cited by 754 · see citing works
Self-citation
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697 · see citing works
Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1
Zhou, X.-Y., Yu, S.-Y., Zhao, D.-M., Harty, J., Badovinac, V., & Xue, H.-H. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.002 · Cited by 689 · see citing works
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 673 · see citing works
The mTOR Kinase Determines Effector versus Memory CD8+ T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin
Rao, R. R., Li, Q., Odunsi, K., & Shrikant, P. A. (2010) · Immunity · doi:10.1016/j.immuni.2009.10.010 · Cited by 656 · see citing works
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.
North, R. J. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.4.1063 · Cited by 650 · see citing works
Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine
Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 646 · see citing works
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624 · see citing works
Vaccines: past, present and future
Plotkin, S. A. (2005) · Nature Medicine · doi:10.1038/nm1209 · Cited by 597 · see citing works
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 596 · see citing works
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials
Ault, K. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60852-6 · Cited by 590 · see citing works
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling
Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586 · see citing works
Self-citation
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N. S., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 576 · see citing works
Self-citation
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Weber, J. S., Thompson, J. A., Hamid, O., Minor, D. R., Amin, A., Ron, I. G., Ridolfi, R., Assi, H. I., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 566 · see citing works
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., & Kawakami, Y. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.6.2539 · Cited by 556 · see citing works
Targeting the innate immune response with improved vaccine adjuvants
Pashine, A., Valiante, N. M., & Ulmer, J. B. (2005) · Nature Medicine · doi:10.1038/nm1210 · Cited by 554 · see citing works
High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells
Serafini, P., Carbley, R., Noonan, K. A., Tan, G. G. Y., Bronte, V., & Borrello, I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0757 · Cited by 524 · see citing works
A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION
Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 518 · see citing works
Improved Endpoints for Cancer Immunotherapy Trials
Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R. A., Anderson, A., Humphrey, R. W., Blumenstein, B. A., Old, L. J., & Wolchok, J. D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 517 · see citing works
CD8 <sup>+</sup> T‐cell memory in tumor immunology and immunotherapy
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511 · see citing works
Self-citation
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
O'Day, S., Maio, M., Chiarion-Sileni, V., Gajewski, T., Pehamberger, H., Bondarenko, I., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 506 · see citing works
Early Programming of T Cell Populations Responding to Bacterial Infection
Mercado, R., Vijh, S., Allen, S. E., Kerksiek, K. M., Pilip, I. M., & Pamer, E. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6833 · Cited by 477 · see citing works
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C., & Restifo, N. P. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.12.003 · Cited by 467 · see citing works
Self-citation
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463 · see citing works
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
Besser, M. J., Shapira‐Frommer, R., Treves, A. J., Zippel, D. B., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462 · see citing works
Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Sharfman, W., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U. S., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 460 · see citing works
Self-citation
Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
Horstmann, E., McCabe, M. S., Grochow, L. B., Yamamoto, S., Rubinstein, L., Budd, T., Shoemaker, D., Emanuel, E., & Grady, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa042220 · Cited by 441 · see citing works
High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
Klapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. A. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 433 · see citing works
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Butts, C. A., Murray, N., Maksymiuk, A. W., Goss, G. D., Marshall, E., Soulières, D., Cormier, Y. F., Ellis, P., Price, A., Sawhney, R. P. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 427 · see citing works
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
Buyse, M. E., Thirion, P. G., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 425 · see citing works
Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation
Bronte, V., Chappell, D. B., Apolloni, E., Cabrelle, A., Wang, M. L., Hwu, P., & Restifo, N. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5728 · Cited by 404 · see citing works
Self-citation
Dynamic programming of CD8+ T lymphocyte responses
van Stipdonk, M. J. B., Hardenberg, G., Bijker, M. S., Lemmens, E. E., Droin, N. M., Green, D. R., & Schoenberger, S. P. (2003) · Nature Immunology · doi:10.1038/ni912 · Cited by 401 · see citing works
Host-reactive CD8+ memory stem cells in graft-versus-host disease
Zhang, Y., Joe, G., Hexner, E., Zhu, J., & Emerson, S. G. (2005) · Nature Medicine · doi:10.1038/nm1326 · Cited by 369 · see citing works
Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma
Dudley, M. E., Wunderlich, J. R., Nishimura, M. I., Yu, D. C., Yang, J. C.-H., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Sherry, R. M., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200107000-00012 · Cited by 361 · see citing works
Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory
Jeannet, G., Boudousquié, C., Gardiol, N., Kang, J., Huelsken, J., & Held, W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914127107 · Cited by 360 · see citing works
Prostate cancer as a model for tumour immunotherapy
Drake, C. G. (2010) · Nature reviews. Immunology · doi:10.1038/nri2817 · Cited by 348 · see citing works
Of Mice but Not Men
Hellmän, S., & Hellman, D. S. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242208 · Cited by 344 · see citing works
Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials
Roberts, T. G. (2004) · JAMA · doi:10.1001/jama.292.17.2130 · Cited by 319 · see citing works
T cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccalà, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15175 · Cited by 316 · see citing works
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Dudley, M. E., Gross, C. A., Langhan, M. M., García, M. R., Sherry, R. M., Yang, J. C.-H., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1297 · Cited by 313 · see citing works
Self-citation
Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas
Marshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K.-Y., Slack, R. S., Hodge, J. W., DOREN, S., Grosenbach, D. W., Hwang, J. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.206 · Cited by 298 · see citing works
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., & Andreesen, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1100 · Cited by 297 · see citing works
Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
Wrzesinski, C., Paulos, C. M., Kaiser, A., Muranski, P. J., Palmer, D. C., Gattinoni, L., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b88ffc · Cited by 284 · see citing works
Self-citation
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
Hoos, A., Parmiani, G., Hege, K. M., Sznol, M., Loibner, H., Eggermont, A. M. M., Urba, W. J., Blumenstein, B. A., Sacks, N., Keilholz, U., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211341.88835.ae · Cited by 270 · see citing works
T cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccalà, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215175 · Cited by 267 · see citing works
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H.-G., Garbe, C., & Pascolo, S. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815ce501 · Cited by 261 · see citing works
Adjuvants for cancer vaccines
Dubensky, T. W., & Reed, S. G. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.04.007 · Cited by 259 · see citing works
Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
Testori, A., Richards, J. M., Whitman, E. D., Mann, G. B., Lutzky, J., Camacho, L. H., Parmiani, G., Tosti, G., Kirkwood, J. M., Hoos, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9941 · Cited by 257 · see citing works
Structural Analysis of CTLA-4 Function In Vivo
Masteller, E. L., Chuang, E., Mullen, A. C., Reiner, S. L., & Thompson, C. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5319 · Cited by 252 · cited 1× · see citing works
“Consequently, under limiting conditions, CTLA-4 may function as a B7 sink (101, 102).”
Background
Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
Smith, F. O., Downey, S. G., Klapper, J. A., Yang, J. C.-H., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Restifo, N. P., Levy, C. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0116 · Cited by 239 · see citing works
Self-citation
Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity
Palucka, A. K., Ueno, H., Connolly, J., Kerneis-Norvell, F., Blanck, J.-P., Johnston, D. A., Fay, J. W., & Banchereau, J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211309.90621.8b · Cited by 234 · see citing works
A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer
Motohashi, S., Nagato, K., Kunii, N., Yamamoto, H., Yamasaki, K., Okita, K., Hanaoka, H., Shimizu, N., Suzuki, M., Yoshino, I., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800126 · Cited by 231 · see citing works
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Weber, J. S. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0653-8 · Cited by 224 · see citing works
Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
Giaccone, G., Debruyne, C., Felip, E., Chapman, P. B., Grant, S. C., Millward, M., Thiberville, L., DʼAddario, G., Coens, C., Rome, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.186 · Cited by 223 · see citing works
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
Izumoto, S., Tsuboi, A., Oka, Y., Suzuki, T., Hashiba, T., Kagawa, N., Hashimoto, N., Maruno, M., Elisseeva, O. A., Shirakata, T., et al. (2008) · Journal of neurosurgery · doi:10.3171/jns/2008/108/5/0963 · Cited by 215 · see citing works
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Kyte, J. A., Mu, L., Aamdal, S., Kvalheim, G., Dueland, S., Hauser, M., Gullestad, H. P., Ryder, T., Lislerud, K., Hammerstad, H., et al. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700961 · Cited by 212 · see citing works
Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
Berthold, D., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M. A., Tannock, A. I. F., & on behalf of the TAX-327 investigators (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0944 · Cited by 207 · see citing works
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 202 · see citing works
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells
Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30414 · Cited by 202 · see citing works
Self-citation
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Amato, R. J., Hawkins, R. E., Kaufman, H. L., Thompson, J. A., Tomczak, P., Szczylik, C. A., McDonald, M., Eastty, S., Shingler, W. H., de Belin, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2082 · Cited by 199 · see citing works
Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer
Vinageras, E. N., de la Torre, A., Rodríguez, M. O., Ferrer, M. C., Cortada, I. B., del Pino, M. M., Abreu, D. A., Brooks, S. A., Rives, R., Carrillo, C. D. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5980 · Cited by 197 · see citing works
“MIATA”—Minimal Information about T Cell Assays
Janetzki, S., Britten, C. M., Kalos, M. D., Levitsky, H. I., Maecker, H. T., Melief, C. J. M., Old, L. J., Romero, P. J., Hoos, A., & Davis, M. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.007 · Cited by 192 · see citing works
Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Sznol, M., Schwarz, S. L., Spiess, P. J., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1690 · Cited by 185 · see citing works
Self-citation
Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer
Nemunaitis, J. J., Jahan, T. M., Ross, H. J., Sterman, D. H., Richards, D., Fox, B. A., Jablons, D. M., Aimi, J., Lin, A., & Hege, K. M. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700922 · Cited by 179 · see citing works
Constitutive Activation of Wnt Signaling Favors Generation of Memory CD8 T Cells
Zhao, D., Yu, S., Zhou, X., Haring, J. S., Held, W., Badovinac, V. P., Harty, J. T., & Xue, H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901199 · Cited by 178 · see citing works
Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy
Gattinoni, L., Ji, Y., & Restifo, N. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0356 · Cited by 175 · see citing works
Self-citation
Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma
Loveland, B. E., Zhao, A., White, S. C., Gan, H. K., Hamilton, K., Xing, P., Pietersz, G. A., Apostolopoulos, V., Vaughan, H. A., Karanikas, V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1574 · Cited by 173 · see citing works
Overall Survival: Still the Gold Standard
Driscoll, J. J., & Rixe, O. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bdc2e0 · Cited by 172 · see citing works
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
Slingluff, C. L., Petroni, G. R., Olson, W. C., Smolkin, M. E., Ross, M. I., Haas, N. B., Grosh, W. W., Boisvert, M. E., Kirkwood, J. M., & Chianese‐Bullock, K. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1544 · Cited by 171 · see citing works
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren, M., Arlen, P. M., Gulley, J. L., Rogatko, A., Cooper, H. S., Meropol, N. J., Alpaugh, R. K., Davey, M., McLaughlin, S. B., Beard, M., et al. (2001) · PubMed · Cited by 171 · see citing works
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial
Harrop, R., Connolly, N. B., Redchenko, I., Valle, J. W., Saunders, M. P., Ryan, M. G., Myers, K. A., Drury, N. L., Kingsman, S. M., Hawkins, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2732 · Cited by 166 · see citing works
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Saenger, Y. M., & Wolchok, J. D. (2008) · PubMed Central · Cited by 164 · see citing works
The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture
DeVita, V. T. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1 · Cited by 164 · see citing works
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
El-Maraghi, R. H., & Eisenhauer, E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5913 · Cited by 152 · see citing works
Transforming growth factor-? in benign and malignant prostate
Lee, C., Sintich, S. M., Mathews, E. P., Shah, A. H., KUNDU, S. D., Perry, K. T., Cho, J. S., Ilio, K. Y., Cronauer, M. V., Janulis, L., et al. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990601)39:4 · Cited by 151 · see citing works
Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
Nemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., Pappen, B., Maples, P. B., Shawler, D., & Fakhrai, H. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.15 · Cited by 147 · see citing works
Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
Madan, R. A., Gulley, J. L., Fojo, T., & Dahut, W. L. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0129 · Cited by 140 · see citing works
Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696
Kirkwood, J. M., Lee, S., Moschos, S. J., Albertini, M. R., Michalak, J. C., Sander, C., Whiteside, T. L., Butterfield, L. H., & Weiner, L. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1231 · Cited by 138 · see citing works
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
Engelhardt, J., Sullivan, T. J., & Allison, J. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1052 · Cited by 137 · see citing works
The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses
Crawford, A., & Wherry, E. J. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.010 · Cited by 134 · see citing works
Vaccination with multiple peptides derived from novel cancer‐testis antigens can induce specific T‐cell responses and clinical responses in advanced esophageal cancer
Kono, K., Mizukami, Y., Daigo, Y., Takano, A., Masuda, K., Yoshida, K., Tsunoda, T., Kawaguchi, Y., Nakamura, Y., & Fujii, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01200.x · Cited by 134 · see citing works
HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan
Kitano, S., Kageyama, S., Nagata, Y., Miyahara, Y., Hiasa, A., Naota, H., Okumura, S., Imai, H., Shiraishi, T., Masuya, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1546 · Cited by 132 · see citing works
Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules
Morse, M. A., Clay, T. M., Hobeika, A. C., Osada, T., Khan, S., Hui, J. Y. C., Niedzwiecki, D., Panicali, D., Schlom, J., & Lyerly, H. K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2172 · Cited by 130 · see citing works
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
Palmer, D. C., Chan, C., Gattinoni, L., Wrzesinski, C., Paulos, C. M., Hinrichs, C. S., Powell, D. J., Klebanoff, C. A., Finkelstein, S. E., Fariss, R. N., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710929105 · Cited by 130 · see citing works
Self-citation
New Therapies for Castration-Resistant Prostate Cancer
Longo, D. L. (2010) · New England Journal of Medicine · doi:10.1056/nejme1006300 · Cited by 127 · see citing works
Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy
Arlen, P. M., Skarupa, L., Pazdur, M. P., Seetharam, M., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., Poole, D. J., Litzinger, M. T., Steinberg, S. M., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.05.117 · Cited by 124 · see citing works
Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL
Goff, S. L., Smith, F. O., Klapper, J. A., Sherry, R. M., Wunderlich, J. R., Steinberg, S. M., White, D., Rosenberg, S. A., Dudley, M. E., & Yang, J. C.-H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f05b91 · Cited by 123 · see citing works
Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma
Butterfield, L. H., Comin-Anduix, B., Vujanovic, L. N., Lee, Y., Dissette, V. B., Yang, J.-Q., Vu, H. T., Seja, E., Oseguera, D. K., Potter, D. M., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31816a8910 · Cited by 121 · see citing works
Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo
Lou, Y., Wang, G., Lizee, G. A., Kim, G. J., Finkelstein, S. E., Feng, C., Restifo, N. P., & Hwu, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1621 · Cited by 121 · see citing works
Self-citation
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
Cheever, M. A., Greenberg, P. D., & Fefer, A. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.2.711 · Cited by 119 · see citing works
Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma
Avigan, D., Vasir, B., George, D. J., Oh, W. K., Atkins, M. B., McDermott, D. F., Kantoff, P. W., Figlin, R. A., Vasconcelles, M. J., Xu, Y., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3180de4ce8 · Cited by 119 · see citing works
Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
Nicholaou, T., Ebert, L. M., Davis, I. D., McArthur, G. A., Jackson, H. M., Dimopoulos, N., Tan, B. S., Maraskovsky, E., Miloradovic, L., Hopkins, W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2484 · Cited by 119 · see citing works
Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens
Slingluff, C. L., Petroni, G. R., Olson, W. C., Czarkowski, A. R., Grosh, W. W., Smolkin, M. E., Chianese‐Bullock, K. A., Neese, P. Y., Deacon, D. H., Nail, C. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3161 · Cited by 118 · see citing works
Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction
Palmer, D. C., Balasubramaniam, S., Hanada, K., Wrzesinski, C., Yu, Z., Farid, S. S., Theoret, M. R., Hwang, L. N., Klebanoff, C. A., Gattinoni, L., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7209 · Cited by 112 · see citing works
Self-citation
Vaccination of Patients With Advanced Non–Small-Cell Lung Cancer With an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide
Bolonaki, I., Kotsakis, A. P., Papadimitraki, E., Aggouraki, D., Konsolakis, G., Vagia, A., Christophyllakis, C., Nikoloudi, I., Magganas, E., Galanis, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3465 · Cited by 108 · see citing works
Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients
Fourcade, J. J., Kudela, P., Filho, P. A. A., Janjic, B. M., Land, S. R., Sander, C., Krieg, A. Μ., Donnenberg, A. D., Shen, H., Kirkwood, J. M., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318183af0b · Cited by 107 · see citing works
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
Svane, I. M., Pedersen, A. E., Johansen, J. S., Johnsen, H. E., Nielsen, D. L., Kamby, C., Ottesen, S., Balslev, E., Gaarsdal, E., Nikolajsen, K., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0293-4 · Cited by 104 · see citing works
Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma
Berntsen, A., Trepiakas, R., Wenandy, L., Geertsen, P. F., Straten, P. T., Andersen, M. H., Pedersen, A. E., Claësson, M. H., Lorentzen, T., Johansen, J. S., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181833818 · Cited by 103 · see citing works
Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer
Barve, M. A., BENDER, J. G., Senzer, N. N., Cunningham, C. C., Greco, F. A., McCune, D. E., Steis, R. G., Khong, H. T., Richards, D., Stephenson, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6462 · Cited by 100 · see citing works
Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma
Fakhrai, H., Mantil, J., Liu, L., Nicholson, G. L., Murphy-Satter, C. S., Ruppert, J. M., & Shawler, D. L. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700975 · Cited by 99 · see citing works
Cancer vaccines: progress reveals new complexities
Yu, Z., & Restifo, N. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16216 · Cited by 97 · see citing works
Self-citation
Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
Ribas, A., Chmielowski, B., & Glaspy, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2376 · Cited by 95 · see citing works
Artificial Antigen-Presenting Cells for Use in Adoptive Immunotherapy
Turtle, C. J., & Riddell, S. R. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb33a6 · Cited by 94 · see citing works
Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
Goffin, J. R., Baral, S., Tu, D., Nomikos, D., & Seymour, L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0130 · Cited by 91 · see citing works
A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma
Uemura, H., Fujimoto, K., Tanaka, M., Yoshikawa, M., Hirao, Y., Uejima, S., Yoshikawa, K., & Itoh, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2253 · Cited by 91 · see citing works
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
Faries, M. B., Hsueh, E. C., Ye, X., Hoban, M., & Morton, D. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1540 · Cited by 91 · see citing works
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Rosenberg, S. A., Yang, J. C.-H., Schwartzentruber, D. J., Hwu, P., Topalian, S. L., Sherry, R. M., Restifo, N. P., Wunderlich, J. R., Seipp, C. A., Rogers-Freezer, L. J., et al. (2003) · PubMed · Cited by 90 · see citing works
Self-citation
Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells
Rapoport, A. P., Stadtmauer, E. A., Aqui, N. A., Vogl, D. T., Chew, A., Fang, H., Janofsky, S., Yager, K., Veloso, E. A., Zheng, Z., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0418 · Cited by 90 · see citing works
A Phase I/II Trial of a WT1 (Wilms' Tumor Gene) Peptide Vaccine in Patients with Solid Malignancy: Safety Assessment Based on the Phase I Data
Morita, S., Oka, Y., Tsuboi, A., Kawakami, M., Maruno, M., Izumoto, S., Osaki, T., Taguchi, T., Ueda, T., Myoui, A., et al. (2006) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyl005 · Cited by 87 · see citing works
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
Schuster, S. J., Neelapu, S. S., Gause, B. L., Muggia, F. M., Gockerman, J. P., Sotomayor, E. M., Winter, J. N., Flowers, C. R., Stergiou, A. M., & Kwak, L. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2 · Cited by 85 · see citing works
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
Tsuruma, T., Iwayama, Y., Ohmura, T., Katsuramaki, T., Hata, F., Furuhata, T., Yamaguchi, K., Kimura, Y., Torigoe, T., TOYOTA, N., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-24 · Cited by 84 · see citing works
Syngeneic Adoptive Immunotherapy and Chemoimmuno-therapy of a Friend Leukemia: Requirement for T cells
Berenson, J. R., Einstein, A. B., & Fefer, A. (1975) · The Journal of Immunology · doi:10.4049/jimmunol.115.1.234 · Cited by 83 · see citing works
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
Kaumaya, P. T. P., Foy, K. C., Garrett, J. T., Rawale, S. V., Vicari, D., Thurmond, J. M., Lamb, T., Mani, A., Kane, Y., Balint, C. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3883 · Cited by 83 · see citing works
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Schwartzentruber, D. J., Lawson, D. J., Richards, J. M., Conry, R. M., Miller, D. M., Triesman, J., Gailani, F., Riley, L., Vena, D. A., & Hwu, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra9011 · Cited by 83 · see citing works
Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma
Weber, J. S., Boswell, W. D., Smith, J. W., Hersh, E. M., Snively, J., Diaz, M. I., Miles, S., Liu, X., Obrocea, M., Qiu, Z., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181611420 · Cited by 82 · see citing works
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
Paesmans, M., Sculier, J., Libert, P., Bureau, G., Dabouis, G., Thiriaux, J., Michel, J., Cutsem, O. V., SERGYSELS, R., Mommen, P., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00325-0 · Cited by 81 · see citing works
NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Gnjatic, S., Altorki, N. K., Tang, D. N., Tu, S., Kundra, V., Ritter, G., Old, L. J., Logothetis, C. J., & Sharma, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2632 · Cited by 79 · see citing works
Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)
Amato, R. J., Shingler, W. H., Goonewardena, M., de Belin, J., Naylor, S., Jac, J., Willis, J., Saxena, S., Hernandez-McClain, J., & Harrop, R. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ace876 · Cited by 78 · see citing works
A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients
Cassaday, R. D., Sondel, P. M., King, D. M., Macklin, M. D., Gan, J., Warner, T. F., Zuleger, C., Bridges, A. J., Schalch, H., Kim, K. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2039 · Cited by 77 · see citing works
Novel Designs and End Points for Phase II Clinical Trials
Adjei, A. A., Christian, M. C., & Ivy, P. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2035 · Cited by 76 · see citing works
Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells
Babatz, J., Röllig, C., Löbel, B., Folprecht, G., Haack, M., Günther, H., Köhne, C., Ehninger, G., Schmitz, M., & Bornhäuser, M. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0021-x · Cited by 69 · see citing works
Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer
Honma, I., Kitamura, H., Torigoe, T., Takahashi, A., Tanaka, T., Sato, E., Hirohashi, Y., Masumori, N., Tsukamoto, T., & Sato, N. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0691-x · Cited by 69 · see citing works
A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression
von Euw, E. M., Barrio, M. M., Furman, D., Levy, E. M., Bianchini, M., Péguillet, I., Lantz, O. J., Vellice, A., Kohan, A. I., Chacon, M. R., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-6 · Cited by 67 · see citing works
Immune Monitoring of T-Cell Responses in Cancer Vaccine Development
Keilholz, U., Martus, P., & Scheibenbogen, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2540 · Cited by 67 · see citing works
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses
Koya, R. C., Mok, S., Comı́n-Anduix, B., Chodon, T., Radu, C. G., Nishimura, M. I., Witte, O. N., & Ribas, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008300107 · Cited by 66 · see citing works
Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients
Lesimple, T., Neidhard, E.-M., Vignard, V., Lefeuvre, C. P., Adamski, H., Labarrière, N., Carsin, A., Monnier, D., Collet, B., Clapisson, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1879 · Cited by 64 · see citing works
Pharmacologic Induction of CD8 + T Cell Memory: Better Living Through Chemistry
Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000302 · Cited by 61 · see citing works
Self-citation
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno, S., Kyo, S., Myojo, S., Dohi, S., Ishizaki, J., Miyamoto, K., Morita, S., Sakamoto, J., Enomoto, T., Kimura, T., et al. (2009) · PubMed · Cited by 59 · see citing works
Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen
Khong, H. T., Yang, J. C.-H., Topalian, S. L., Sherry, R. M., Mavroukakis, S. A., White, D. E., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00007 · Cited by 55 · see citing works
A Phase I Study of the Optimized Cryptic Peptide TERT572Y in Patients with Advanced Malignancies
Mavroudis, D., Bolonakis, I., Cornet, S., Myllaki, G., Kanellou, P., Kotsakis, A. P., Galanis, A., Nikoloudi, I., Spyropoulou, M., Menez, J., et al. (2006) · Oncology · doi:10.1159/000096252 · Cited by 55 · see citing works
The In vivo Expansion Rate of Properly Stimulated Transferred CD8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor
Hwang, L. N., Yu, Z., Palmer, D. C., & Restifo, N. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1679 · Cited by 53 · see citing works
Self-citation
Dendritic cell immunotherapy for stage IV melanoma
OʼRourke, M. G. E., Johnson, M. K., Lanagan, C. M., See, J. L., O’Connor, L., Slater, G. J., Thomas, D. M., López, J. A., Martinez, N. R., Ellem, K. A. O., et al. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e3282c3a73b · Cited by 51 · see citing works
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Schwartzentruber, D. J., Lawson, D. J., Richards, J., Conry, R. M., Miller, D., Triesman, J., Gailani, F., Riley, L. B., Vena, D. A., & Hwu, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.cra9011 · Cited by 51 · see citing works
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma
Powell, A., Creaney, J., Broomfield, S., van Bruggen, I., & Robinson, B. W. S. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.01.007 · Cited by 50 · see citing works
Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma
Lindsey, K. R., Gritz, L. R., Sherry, R. M., Abati, A. D., Fetsch, P. A., Goldfeder, L. C., Gonzales, M. I., Zinnack, K., Rogers-Freezer, L. J., Haworth, L. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2061 · Cited by 50 · see citing works
Self-citation
Immune response to vaccination with DNA-hsp65 in a phase I clinical trial with head and neck cancer patients
Victora, G. D., Socorro-Silva, A., Volsi, E. C., Abdallah, K., Lima, F. D., Smith, R. B., Moysés, R. A., Zárate-Bladés, C. R., Michaluart, P., Silva, C. L., et al. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.9 · Cited by 49 · see citing works
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432
Aoki, M., Ueda, S., Nishikawa, H., Kitano, S., Hirayama, M., Ikeda, H., Toyoda, H., Tanaka, K., Kanai, M., Takabayashi, A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.018 · Cited by 49 · see citing works
Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma
Bachleitner‐Hofmann, T. (2009) · Oncology Reports · doi:10.3892/or_00000391 · Cited by 46 · see citing works
Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy
Okaji, Y., Tsuno, N. H., Tanaka, M., Yoneyama, S., Matsuhashi, M., Kitayama, J., Saito, S., Nagura, Y., Tsuchiya, T., Yamada, J., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.018 · Cited by 44 · see citing works
Landmark approval for Dendreon's cancer vaccine
DeFrancesco, L. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-531 · Cited by 44 · see citing works
Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice
Lin, G. H. Y., Liu, Y., Ambagala, T., Kwon, B. S., Ohashi, P. S., & Watts, T. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011003 · Cited by 43 · see citing works
TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation
de Witte, M. A., Bendle, G. M., van den Boom, M. D., Coccoris, M., Schell, T. D., Tevethia, S. S., van Tinteren, H., Mesman, E. M., Song, J., & Schumacher, T. N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2563 · Cited by 41 · see citing works
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
Schuster, S. J., Neelapu, S. S., Gause, B. L., Muggia, F. M., Gockerman, J. P., Sotomayor, E. M., Winter, J. N., Flowers, C. R., Stergiou, A. M., & Kwak, L. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.2 · Cited by 39 · see citing works
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: Results of a phase Ib/IIa study
Osorio, M., Gracia, E., Rodríguez, E., Saurez, G., Arango, M. D. C., Noris, E., Torriella, A., Joan, A., Gómez, E., Anasagasti, L., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.4.5476 · Cited by 38 · see citing works
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma
Celis, E. (2007) · Cancer · doi:10.1002/cncr.22744 · Cited by 38 · see citing works
Spontaneous regression of metastases from malignant melanoma: a case report
Kalialis, L. V., Drzewiecki, K. T., Mohammadi, M., Mehlsen, A.-B., & Klyver, H. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e328307ee4c · Cited by 37 · see citing works
Phase I trial of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patients
Suekane, S., Nishitani, M., Noguchi, M., Komohara, Y., Kokubu, T., Naitoh, M., Honma, S., Yamada, A., Itoh, K., Matsuoka, K., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00631.x · Cited by 36 · see citing works
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes
Ugel, S., Scarselli, E., Iezzi, M., Mennuni, C., Pannellini, T., Calvaruso, F., Cipriani, B., Palma, R. D., Ricci‐Vitiani, L., Peranzoni, E., et al. (2009) · Blood · doi:10.1182/blood-2009-07-233270 · Cited by 33 · see citing works

Flagged first, then by citations

Research works printed but not linked: 7

[58]Madan RA Gulley JL Fojo T Dahut WL Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression Oncologist 2010 PMC3228037 20798195
[81]Rosenberg SA Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma J Immunol 2005 175 6169 6176 16237114
[117]Overwijk WW Theoret MR Finkelstein SE Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells J Exp Med 2003 198 569 580 12925674 PMC2194177
[156]Besser MJ Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients Clin Cancer Res 2010 16 2646 2655 20406835
[193]Marshall JL Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas J Clin Oncol 2005 23 720 731 15613691
[212]Higano C A Phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium 2009 2009
[213]Small E A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium 2009 2009

Sorted by citations

Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works
Self-citation
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · see citing works
Self-citation
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,058 · see citing works
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869 · see citing works
The Basis of Oncoimmunology
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843 · see citing works
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 770 · see citing works
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 596 · see citing works
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514 · see citing works
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami‐Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 495 · see citing works
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449 · see citing works
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407 · see citing works
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 366 · see citing works
Self-citation
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Kakarla, S., Chow, K. K. H., Mata, M., Shaffer, D. R., Song, X., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.110 · Cited by 347 · see citing works
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
van Montfoort, N., Borst, L., Korrer, M. J., Sluijter, M., Marijt, K. A., Santegoets, S. J. A. M., van Ham, V. J., Ehsan, I., Charoentong, P., André, P., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.028 · Cited by 334 · see citing works
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 325 · see citing works
Self-citation
Immune microenvironments in solid tumors: new targets for therapyPreprint
Shiao, S. L., Ganesan, A.-P., Rugo, H. S., & Coussens, L. M. (2011) · Genes & Development · doi:10.1101/gad.169029.111 · Cited by 320 · see citing works
Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P. J., Ji, Y., Hinrichs, C. S., Borman, Z. A., Kerkar, S. P., Scott, C. D., Finkelstein, S. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0503 · Cited by 288 · see citing works
Self-citation
Recent applications of immunomodulatory biomaterials for disease immunotherapy
Dai, H., Fan, Q., & Wang, C. (2022) · Exploration · doi:10.1002/exp.20210157 · Cited by 270 · see citing works
Metallic nanoparticles for cancer immunotherapy
Evans, E. R., Bugga, P., Asthana, V., & Drezek, R. A. (2017) · Materials Today · doi:10.1016/j.mattod.2017.11.022 · Cited by 244 · see citing works
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 243 · see citing works
Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy
Chew, V., Toh, H. C., & Abastado, J. (2012) · Journal of Oncology · doi:10.1155/2012/608406 · Cited by 217 · see citing works
Adoptive T-Cell Therapy for Cancer
Yang, J. C.-H., & Rosenberg, S. A. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 205 · see citing works
Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection
Aubert, R. D., Kamphorst, A. O., Sarkar, S., Vezys, V., Ha, S., Barber, D. L., Ye, L., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118450109 · Cited by 198 · see citing works
Extracellular Matrix‐Based Strategies for Immunomodulatory Biomaterials Engineering
Rowley, A. T., Nagalla, R. R., Wang, S., & Liu, W. F. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801578 · Cited by 193 · see citing works
Impact of the immune system and immunotherapy in colorectal cancer.
Markman, J. L., & Shiao, S. L. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.077 · Cited by 196 · see citing works
Targeting public neoantigens for cancer immunotherapy
Pearlman, A. H., Hwang, M. S., Konig, M. F., Hsiue, E. H.-C., Douglass, J., DiNapoli, S. R., Mog, B. J., Bettegowda, C., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00210-y · Cited by 192 · see citing works
The role of B7 family molecules in hematologic malignancy
Greaves, P., & Gribben, J. G. (2012) · Blood · doi:10.1182/blood-2012-10-385591 · Cited by 188 · see citing works
Updates on immunotherapy for colorectal cancer
Kalyan, A., Kircher, S. M., Shah, H. A., Mulcahy, M. F., & Benson, A. B. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.17 · Cited by 178 · see citing works
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy
Crane, C. A., Ahn, B. J., Han, S. J., & Parsa, A. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos014 · Cited by 169 · see citing works
Tumor cell lysates as immunogenic sources for cancer vaccine design
González, F. E., Gleisner, M. A., Falcón-Beas, F., Osorio, F., López, M. N., & Salazar‐Onfray, F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.982996 · Cited by 160 · see citing works
Retinoic acid controls the homeostasis of pre-cDC–derived splenic and intestinal dendritic cells
Klebanoff, C. A., Spencer, S. P., Torabi‐Parizi, P., Grainger, J. R., Roychoudhuri, R., Ji, Y., Sukumar, M., Muranski, P. J., Scott, C. D., Hall, J. A., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20122508 · Cited by 157 · see citing works
Self-citation
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
Eid, R. A., Samara, R. N., Ozbun, L. L., Abdalla, M. Y., Berzofsky, J. A., Friedman, K. M., Mkrtichyan, M., & Khleif, S. N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0095 · Cited by 154 · see citing works
Biomimetic Protein Nanoparticles Facilitate Enhanced Dendritic Cell Activation and Cross-Presentation
Molino, N. M., Anderson, A. K. L., Nelson, E. L., & Wang, S. (2013) · ACS Nano · doi:10.1021/nn403085w · Cited by 153 · see citing works
The split nature of tumor-infiltrating leukocytes
Lança, T., & Silva‐Santos, B. (2012) · OncoImmunology · doi:10.4161/onci.20068 · Cited by 148 · see citing works
Tumor Microenvironment and Myeloid-Derived Suppressor Cells
Umansky, V., & Sevko, A. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0126-7 · Cited by 141 · see citing works
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Raval, R. R., Sharabi, A. B., Walker, A. J., Drake, C. G., & Sharma, P. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-14 · Cited by 140 · see citing works
Combination of Radiotherapy and Immune Checkpoint Inhibitors
Pilones, K. A., Vanpouille‐Box, C., & Demaria, S. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.004 · Cited by 136 · see citing works
Natural and Synthetic Saponins as Vaccine Adjuvants
Wang, P. (2021) · Vaccines · doi:10.3390/vaccines9030222 · Cited by 129 · see citing works
The Abscopal Effect of Radiation Therapy
Craig, D. J., Nanavaty, N. S., Devanaboyina, M., Stanbery, L., Hamouda, D., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2021) · Future Oncology · doi:10.2217/fon-2020-0994 · Cited by 129 · see citing works
Melanoma-induced immunosuppression and its neutralization
Umansky, V., & Sevko, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.003 · Cited by 128 · see citing works
A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients
Vetsika, E., Koinis, F., Gioulbasani, M., Aggouraki, D., Koutoulaki, A., Skalidaki, E., Mavroudis, D., Georgoulias, V., & Kotsakis, A. P. (2014) · Journal of Immunology Research · doi:10.1155/2014/659294 · Cited by 121 · see citing works
Telomerase and the search for the end of cancer
D, S. M. M., Pooley, K. A., & Nitti, D. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.11.006 · Cited by 121 · see citing works
Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
Zanetti, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402669 · Cited by 119 · see citing works
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation
Papaspyridonos, M., Matei, I. R., Huang, Y., André, M. D. R., Brazier, H., Waite, J. C., Chan, A., Kalter, J., Ramos, I., Wu, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms7840 · Cited by 115 · see citing works
Immunotherapies for non-small-cell lung cancer and mesothelioma
Thomas, A., & Hassan, R. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70126-2 · Cited by 110 · see citing works
Cutaneous melanoma and the immunotherapy revolution (Review)
Leonardi, G. C., Candido, S., Falzone, L., Spandidos, D. A., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5088 · Cited by 106 · see citing works
Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy
Kondo, T., Morita, R., Okuzono, Y., Nakatsukasa, H., Sekiya, T., Chikuma, S., Shichita, T., Kanamori, M., Kubo, M., Koga, K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15338 · Cited by 104 · see citing works
Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy
Ramakrishnan, R., Huang, C., Cho, H.-I., Lloyd, M. C., Johnson, J., Ren, X., Altiok, S., Sullivan, D. M., Weber, J. S., Celis, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2236 · Cited by 102 · see citing works
Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer
Mondini, M., Nizard, M., Tran, T., Mauge, L., Loi, M., Clémenson, C., Dugué, D., Maroun, P., Louvet, E., Adam, J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1015 · Cited by 97 · see citing works
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon‐mediated rejection genes
Carretero, R., Wang, E., Rodríguez, A. I. E., Reinboth, J., Ascierto, M. L., Engle, A. M., Liu, H., Camacho, F. M., Marincola, F. M., Garrido, F., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26471 · Cited by 88 · see citing works
Clinically feasible approaches to potentiating cancer cell-based immunotherapies
Seledtsov, V. I., Гончаров, А. Г., & Seledtsova, G. V. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1009814 · Cited by 87 · see citing works
Regulation of mature T cell responses by the Wnt signaling pathway
Xue, H., & Zhao, D. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06302.x · Cited by 88 · see citing works
ImmTACs for targeted cancer therapy: Why, what, how, and which
Oates, J., Hassan, N. J., & Jakobsen, B. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.024 · Cited by 87 · see citing works
Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy
Zhang, Y., Fang, Z., Li, R., Huang, X., & Liu, Q. (2019) · Cancers · doi:10.3390/cancers11091314 · Cited by 85 · see citing works
Metastatic melanoma treatment: Combining old and new therapies
Davey, R. J., van der Westhuizen, A., & Bowden, N. A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.011 · Cited by 82 · see citing works
Immunotherapy for metastatic solid cancers
Turcotte, S., & Rosenberg, S. A. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.04.003 · Cited by 81 · see citing works
Functional differences between low- and high-affinity CD8+T cells in the tumor environment
Bos, R., Marquardt, K., Cheung, J., & Sherman, L. A. (2012) · OncoImmunology · doi:10.4161/onci.21285 · Cited by 80 · see citing works
Structural and dynamic control of T‐cell receptor specificity, cross‐reactivity, and binding mechanism
Baker, B. M., Scott, D. R., Blevins, S. J., & Hawse, W. F. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01165.x · Cited by 80 · see citing works
Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice
Gagliato, D. D. M., Cortés, J., Curigliano, G., Loi, S., Denkert, C., Pérez-García, J. M., & Holgado, E. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.003 · Cited by 80 · see citing works
Immunomodulatory and anticancer potential of Gan cao (Glycyrrhiza uralensis Fisch.) polysaccharides by CT-26 colon carcinoma cell growth inhibition and cytokine IL-7 upregulation in vitro
Ayeka, P. A., Bian, Y., Mwitari, P., Chu, X., Zhang, Y., Uzayisenga, R., & Otachi, E. O. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1171-4 · Cited by 79 · see citing works
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
Reustle, A., Marco, M. D., Meyerhoff, C., Nelde, A., Walz, J. S., Winter, S., Kandabarau, S., Büttner, F., Haag, M., Backert, L., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00731-8 · Cited by 76 · see citing works
Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles
Grandi, A., Tomasi, M., Zanella, I., Ganfini, L., Caproni, E., Fantappiè, L., Irene, C., Frattini, L. F., Isaac, S. J., König, E., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00253 · Cited by 78 · see citing works
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
Zandberg, D. P., Rollins, S., Goloubeva, O. G., Morales, R. E., Tan, M. T., Taylor, R., Wolf, J. S., Schumaker, L. M., Cullen, K. J., Zimrin, A. B., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1640-x · Cited by 77 · see citing works
Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor
McGray, A. R., Hallett, R. M., Bernard, D., Swift, S. L., Zhu, Z., Teoderascu, F., VanSeggelen, H., Hassell, J. A., Hurwitz, A. A., Wan, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.255 · Cited by 75 · see citing works
Telomerase as a Cancer Target. Development of New Molecules
Gómez, D. L. M., Armando, R. G., Cerrudo, C. S., Ghiringhelli, P. D., & Gomez, D. E. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160212122425 · Cited by 75 · see citing works
The emerging role of immunotherapy in colorectal cancer
Lynch, D. H., & Murphy, A. G. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.08.29 · Cited by 75 · see citing works
CD56dim CD16− Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α
Vujanovic, L. N., Chuckran, C. A., Lin, Y., Ding, F., Sander, C., Santos, P. M. L., Lohr, J., Mashadi-Hossein, A., Warren, S. E., White, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00014 · Cited by 75 · see citing works
Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response
Garu, A., Moku, G., Gulla, S. K., & Chaudhuri, A. (2015) · Molecular Therapy · doi:10.1038/mt.2015.215 · Cited by 73 · see citing works
Effective Cancer Vaccine Platform Based on Attenuated Salmonella and a Type III Secretion System
Xu, X. Y., Hegazy, W. A. H., Guo, L., Gao, X., Courtney, A. N., Kurbanov, S., Liu, D., Tian, G., Manuel, E. R., Diamond, D. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1169 · Cited by 72 · see citing works
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 69 · see citing works
Harnessing the Microbiome to Enhance Cancer Immunotherapy
Nelson, M. H., Diven, M. A., Huff, L. W., & Paulos, C. M. (2015) · Journal of Immunology Research · doi:10.1155/2015/368736 · Cited by 70 · see citing works
Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors
Zurac, S., Neagu, M. T., Constantin, C., Cioplea, M. D., Nedelcu, R., Bastian, A. E., Popp, C. G., Nichita, L., Andrei, R. T., Tebeică, T., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4391 · Cited by 69 · see citing works
Extracellular adenosine metabolism in immune cells in melanoma
Umansky, V., Shevchenko, I., Bazhin, A. V., & Utikal, J. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1553-8 · Cited by 68 · see citing works
Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes
Feichtinger, J., Aldeailej, I. M., Anderson, R., Almutairi, M. H., Almatrafi, A., Alsiwiehri, N. O., Griffiths, K., Stuart, N. S. A., Wakeman, J. A., Larcombe, L. D., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.580 · Cited by 66 · see citing works
Genetic cancer vaccines: current status and perspectives
Aurisicchio, L., & Ciliberto, G. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.689279 · Cited by 65 · see citing works
Immunotherapy in colorectal cancer: for the select few or all?
Arora, S. P., & Mahalingam, D. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.06.10 · Cited by 65 · see citing works
The role played by the microenvironment in site-specific metastasis
Klein-Goldberg, A., Maman, S., & Witz, I. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.029 · Cited by 64 · see citing works
Shared cancer neoantigens: Making private matters public
Klebanoff, C. A., & Wolchok, J. D. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20172188 · Cited by 62 · see citing works
Self-citation
Melanoma therapeutics: a literature review
Dhanyamraju, P. K., & Patel, T. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20210163 · Cited by 61 · see citing works
Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines
Ciocca, D. R., Cayado-Gutiérrez, N., Maccioni, M., & Cuello-Carrión, F. D. (2012) · Current Molecular Medicine · doi:10.2174/156652412803306684 · Cited by 59 · see citing works
Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy
Calmeiro, J., Carrascal, M. A., Gomes, C. M. F., Falcão, A. C., Cruz, M. T., & Neves, B. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0716-8 · Cited by 59 · see citing works
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level
Grenier, J. M., Yeung, S. T., & Khanna, K. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00610 · Cited by 58 · see citing works
Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging
Hartimath, S. V., Draghiciu, O., van de Wall, S., Manuelli, V., Dierckx, R., Nijman, H. W., Daemen, T., & de Vries, E. F. J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1248014 · Cited by 57 · see citing works
Improving T cell responses to modified peptides in tumor vaccines
Buhrman, J. D., & Slansky, J. E. (2012) · Immunologic Research · doi:10.1007/s12026-012-8348-9 · Cited by 54 · see citing works
Generation and application of human induced‐stem cell memory T cells for adoptive immunotherapy
Kondo, T., Imura, Y., Chikuma, S., Hibino, S., Omata‐Mise, S., Ando, M., Akanuma, T., Iizuka, M., Sakai, R., Morita, R., et al. (2018) · Cancer Science · doi:10.1111/cas.13648 · Cited by 51 · see citing works
Various ways to improve whole cancer cell vaccines
Cicchelero, L., de Rooster, H., & Sanders, N. N. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.911093 · Cited by 51 · see citing works
Therapeutic vaccines for colorectal cancer: The progress and future prospect
Shahnazari, M., Samadi, P., Pourjafar, M., & Jalali, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106944 · Cited by 52 · see citing works
Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma
Butterfield, L. H., Vujanovic, L. N., Santos, P. M. L., Maurer, D. M., Gambotto, A. A., Lohr, J., Li, C., Waldman, J., Chandran, U. R., Lin, Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0552-x · Cited by 50 · see citing works
Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis
Vo, J., Yang, L., Kurtz, S. L., Smith, S. G., Koppolu, B., Ravindranathan, S., & Zaharoff, D. A. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968001 · Cited by 49 · see citing works
Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses
Ghinnagow, R., Meester, J. D., Cruz, L. J., Aspord, C., Corgnac, S., Fernandez, É. M., Soulard, D., Fontaine, J., Chaperot, L., Charles, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1339855 · Cited by 49 · see citing works
The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes
Duechler, M., Pęczek, Ł., Żuk, K., Zaleśna, I., Jeziorski, A., & Czyż, M. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.09.003 · Cited by 48 · see citing works
Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park, J., Thomas, S., & Munster, P. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 49 · see citing works
Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice
Najima, Y., Tomizawa-Murasawa, M., Saito, Y., Watanabe, T., Ono, R., Ochi, T., Suzuki, N., Fujiwara, H., Ohara, O., Shultz, L. D., et al. (2015) · Blood · doi:10.1182/blood-2014-10-604777 · Cited by 47 · see citing works
Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment
Baharom, F., Hermans, D., Delamarre, L., & Seder, R. A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01091-9 · Cited by 47 · see citing works
HLA-A*0201 Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients
Aspord, C., Leccia, M. ‐., Salameire, D., Laurin, D., Chaperot, L., Charles, J., & Plumas, J. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.152 · Cited by 46 · see citing works
CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice
Hansen, J. U., Lindenstrøm, T., Lindberg-Levin, J., Aagaard, C., Andersen, P. L., & Agger, E. M. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1156-6 · Cited by 45 · see citing works
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic
Breitbach, C. J., Parato, K. A., Burke, J., Hwang, T.-H., Bell, J. C., & Kirn, D. H. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.016 · Cited by 44 · see citing works
Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection
Jin, J., Zhu, P., Liao, Y., Li, J., Liao, W., & He, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4265 · Cited by 41 · see citing works
Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers
Cho, S., Dong, S., Parent, K. N., & Chen, M. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1077847 · Cited by 41 · see citing works
Immunotherapy for malignant glioma
Suryadevara, C. M., Sanchez-Perez, L. A., Sampson, J. H., Verla, T. G., Reap, E. A., Choi, B., & Fecci, P. E. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.151341 · Cited by 41 · see citing works

Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597 · see citing works
A review on cancer vaccines: Current developments and future prospects
CHANDANA, J. V. S., Renu, J., Swathi, E., Varsha, D., & RAMARAO, T. (2025) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2025.21.1.1018 · Cited by 1 · see citing works
Next-generation cancer vaccines and emerging immunotherapy combinations
Brandenburg, A., Heine, A., & Brossart, P. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.003 · Cited by 52 · see citing works
Therapeutic Cancer Vaccines: Mechanisms, Clinical Evidence and Translational Challenges
Nasika, R. (2026) · American journal of student research. · doi:10.70251/hyjr2348.42215222
Therapeutic cancer vaccines: development, challenges, and future perspectives
Di, D., Li, L.-F., He, T.-Y., Cui, H.-X., Nian, Y., Jiao, X., Han, C.-Y., & Wei, M. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01928-0 · Cited by 1 · see citing works

Authors: Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P.
Affiliations: National Institutes of Health (US)
Corresponding author: Restifo, Nicholas P.
ORCID: Klebanoff, Christopher A.
Yu, Zhiya
Restifo, Nicholas P.
Venue: Immunological Reviews
Publisher: Wiley
Published: 2010-12-28
Volume: 239
Issue: 1
Pages: 27-44
ISSN: 0105-2896 (ISSN-L)
1600-065X
DOI: 10.1111/j.1600-065x.2010.00979.x
PMC: PMC3075547
OpenAlex: W2132361489
Cited by: 271
References: 210
Citations by year: 2026: 2 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 19 · 2018: 14 · 2017: 16 · 2016: 21 · 2015: 36 · 2014: 22 · 2013: 33 · 2012: 34
FWCI: 2.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Immunological Reviews (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (ZIABC010763, ZIABC011037)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: therapeutic cancer vaccines, adoptive cell transfer, tumor microenvironment, regulatory T cells, myeloid cells, T cell exhaustion, tumor antigen loss, immune evasion, immunoadjuvant, immune checkpoint blockade, metastatic cancer, clinical trial efficacy
MeSH terms: Adjuvants, Immunologic, Antigens, Differentiation, T-Lymphocyte, Antigens, Neoplasm, Humans, Immunotherapy, Neoplasms, Randomized Controlled Trials as Topic, T-Lymphocyte Subsets, Treatment Outcome, Adoptive Transfer, Cancer Vaccines, Toll-Like Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic cancer vaccines: Are we there yet?

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks